Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data
from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast
2018, taking place from November 28-30, 2018 in San Diego, California.
Details of the presentation are as follows:
The Phase 2 study was completed with support from Biomedical Advanced Research and Development Authority (BARDA). Vaxart
received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza
vaccines to ultimately improve seasonal and pandemic influenza preparedness. The contract was increased to $15.7 million in
2017.
The project has been funded in whole or in part with federal funds from the Department of Health and Human Services’ Office of
the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No.
HHSO100201500034C.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect
against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer.
Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes
that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly
increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus
(HPV). For more information, please visit
www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release regarding our strategy, prospects, plans and objectives,
results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be accompanied by such words as “believe,” “could,” “potential”,
“will” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data; and the
potential of its product candidates to significantly increase vaccination rates. Vaxart may not actually achieve the plans, carry
out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place
undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements that Vaxart makes, that Vaxart’s product candidates may not be
approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities,
Vaxart’s product candidates may not achieve broad market acceptance; that Vaxart may experience manufacturing issues and delays;
and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly Reports filed on Form 10-Q and of Vaxart’s other
periodic reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as
required by law.
Carl Mauch
Stern Investor Relations
212-362-1200
vaxart@sternir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005175/en/